// App-Quantinova.ai

: PTPN11 Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph+ ALL Cells, but Are Sensitive to the Combination

Researchers

Presenter

  • Govinda Poudel

Principal Investigators

  • David T Yeung

  • Deborah L White

  • Timothy Hughes

  • Ilaria S Pagani

Medical Centers

  • Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia

  • School of Medicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia

  • South Australian Health and Medical Research Institute SAHMRI, Adelaide, Australia

  • Department of Paediatrics, The University of Adelaide, Adelaide, Australia

  • Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia

  • School of Biological Sciences, The University of Adelaide, Adelaide, Australia

  • Australasian Leukaemia and Lymphoma Group (ALLG), Melbourne, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Annexin V

  • Breakpoint Cluster Region

  • Protein Tyrosine Phosphatase, Non-Receptor Type 11

Drug/Treatment

  • Venetoclax

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved